Scholarlink

Background <p>Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, particularly in low- and middle-income countries. In Iran, where the prevalence of ROP among premature infants exceeds 20%, limited access to subspecialist ophthalmologists constrains timely screening. This study evaluated the cost–utility of three alternative ROP screening strategies to inform national policy on optimizing resource allocation.</p> Methods <p>A lifetime, societal-perspective cost–utility analysis was conducted using a state-transition Markov model. Three strategies were compared: (1) universal referral of all at-risk infants to tertiary centers; (2) RetCam-based nurse-led imaging with remote ophthalmologist review (telemedicine); and (3) local screening by general ophthalmologists with selective referral. Model inputs were derived from national data, published literature, and expert opinion. Costs (2025 Iranian Tomans) and quality-adjusted life years (QALYs) were discounted at 5.8%. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty.</p> Results <p>The Direct Examination scenario (general ophthalmologist screening) had the lowest mean cost (33.52 USD) and effectiveness (16.83 QALYs). RetCam imaging achieved higher effectiveness (17.14 QALYs) at a cost of 122.69 USD, yielding an incremental cost-effectiveness ratio (ICER) of 288.81 USD per QALY gained, well below Iran’s willingness-to-pay (WTP) threshold of USD 7,047. The Universal Referral strategy was dominated, being both more costly and less effective. Probabilistic sensitivity analysis confirmed that RetCam imaging was cost-effective in 95.2% of 10,000 Monte Carlo simulations at a WTP of USD 6,000 per QALY. Diagnostic specificity and long-term vision care costs were the key ICER drivers.</p> Conclusions <p>RetCam-based telemedicine screening for ROP in Iran is highly cost-effective compared to traditional direct examination or universal referral, offering substantial long-term health gains at an acceptable cost. Scaling up telemedicine screening, supported by quality assurance and training programs, could reduce preventable childhood blindness and improve efficiency of neonatal eye care delivery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost–utility analysis of retinopathy of prematurity screening strategies of universal referral, RetCam telemedicine, and direct examination in Iran: a markov model approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Parinaz Alizadeh,
  • Maryam Manaberi,
  • Afsar Dastjani Farahani,
  • Cyrus Alinia

摘要

Background

Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness, particularly in low- and middle-income countries. In Iran, where the prevalence of ROP among premature infants exceeds 20%, limited access to subspecialist ophthalmologists constrains timely screening. This study evaluated the cost–utility of three alternative ROP screening strategies to inform national policy on optimizing resource allocation.

Methods

A lifetime, societal-perspective cost–utility analysis was conducted using a state-transition Markov model. Three strategies were compared: (1) universal referral of all at-risk infants to tertiary centers; (2) RetCam-based nurse-led imaging with remote ophthalmologist review (telemedicine); and (3) local screening by general ophthalmologists with selective referral. Model inputs were derived from national data, published literature, and expert opinion. Costs (2025 Iranian Tomans) and quality-adjusted life years (QALYs) were discounted at 5.8%. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty.

Results

The Direct Examination scenario (general ophthalmologist screening) had the lowest mean cost (33.52 USD) and effectiveness (16.83 QALYs). RetCam imaging achieved higher effectiveness (17.14 QALYs) at a cost of 122.69 USD, yielding an incremental cost-effectiveness ratio (ICER) of 288.81 USD per QALY gained, well below Iran’s willingness-to-pay (WTP) threshold of USD 7,047. The Universal Referral strategy was dominated, being both more costly and less effective. Probabilistic sensitivity analysis confirmed that RetCam imaging was cost-effective in 95.2% of 10,000 Monte Carlo simulations at a WTP of USD 6,000 per QALY. Diagnostic specificity and long-term vision care costs were the key ICER drivers.

Conclusions

RetCam-based telemedicine screening for ROP in Iran is highly cost-effective compared to traditional direct examination or universal referral, offering substantial long-term health gains at an acceptable cost. Scaling up telemedicine screening, supported by quality assurance and training programs, could reduce preventable childhood blindness and improve efficiency of neonatal eye care delivery.